Tags

Type your tag names separated by a space and hit enter

Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.
Hiroshima J Med Sci. 2011 Sep; 60(3):57-62.HJ

Abstract

The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone.

Authors+Show Affiliations

Department of Clinical Neuroscience and Therapeutics, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22053701

Citation

Ishihara, Aiko, et al. "Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease." Hiroshima Journal of Medical Sciences, vol. 60, no. 3, 2011, pp. 57-62.
Ishihara A, Miyachi T, Nakamura T, et al. Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. Hiroshima J Med Sci. 2011;60(3):57-62.
Ishihara, A., Miyachi, T., Nakamura, T., Ohtsuki, T., Kimura, Y., Kihira, K., Yamawaki, T., & Matsumoto, M. (2011). Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. Hiroshima Journal of Medical Sciences, 60(3), 57-62.
Ishihara A, et al. Relationship Between 3-O-methyldopa and the Clinical Effects of Entacapone in Advanced Parkinson's Disease. Hiroshima J Med Sci. 2011;60(3):57-62. PubMed PMID: 22053701.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. AU - Ishihara,Aiko, AU - Miyachi,Takafumi, AU - Nakamura,Takeshi, AU - Ohtsuki,Toshiho, AU - Kimura,Yasuhiro, AU - Kihira,Kenji, AU - Yamawaki,Takemori, AU - Matsumoto,Masayasu, PY - 2011/11/8/entrez PY - 2011/11/8/pubmed PY - 2011/12/13/medline SP - 57 EP - 62 JF - Hiroshima journal of medical sciences JO - Hiroshima J Med Sci VL - 60 IS - 3 N2 - The aim of this study is to clarify the relationship between serum 3-O-methyldopa (3-OMD) and the clinical effects of entacapone. The 3-OMD and maximum serum concentration (Cmax) of levodopa were measured in 21 Parkinson's Disease patients who took 100 mg levodopa / dopa decarboxylase inhibitor. After the administration of entacapone, the 3-OMD concentration and percentage of "on" time during waking hours (% of "on" time) were studied for 8 weeks. The 3-OMD concentration was reduced by 34%, and the increase in % of "on" time was 28% at the 8th week compared with baseline. We defined the COMT-index as [baseline 3-OMD concentration] / [levodopa Cmax when 100 mg levodopa was administered alone]. The COMT-index was significantly correlated with the increase in % of "on" time at the 8th week. In conclusion, the measurement of baseline 3-OMD and levodopa pharmacokinetics is useful for predicting the clinical effects of entacapone. SN - 0018-2052 UR - https://www.unboundmedicine.com/medline/citation/22053701/Relationship_between_3_O_methyldopa_and_the_clinical_effects_of_entacapone_in_advanced_Parkinson's_disease_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -